Your browser is no longer supported. Please, upgrade your browser.
AMGN Amgen Inc. daily Stock Chart
Amgen Inc.
IndexS&P 500 P/E14.94 EPS (ttm)12.61 Insider Own0.10% Shs Outstand631.16M Perf Week1.26%
Market Cap118.87B Forward P/E12.64 EPS next Y14.90 Insider Trans-3.63% Shs Float630.92M Perf Month-5.30%
Income8.39B PEG7.47 EPS next Q3.48 Inst Own80.00% Short Float1.61% Perf Quarter-1.68%
Sales23.75B P/S5.01 EPS this Y7.30% Inst Trans0.18% Short Ratio3.15 Perf Half Y-3.54%
Book/sh22.25 P/B8.46 EPS next Y6.07% ROA3.30% Target Price204.62 Perf Year4.91%
Cash/sh47.41 P/C3.97 EPS next 5Y2.00% ROE13.50% 52W Range163.31 - 210.19 Perf YTD-3.25%
Dividend5.80 P/FCF16.62 EPS past 5Y14.40% ROI14.00% 52W High-10.40% Beta1.21
Dividend %3.08% Quick Ratio2.80 Sales past 5Y5.80% Gross Margin83.90% 52W Low15.33% ATR3.83
Employees20800 Current Ratio3.10 Sales Q/Q2.30% Oper. Margin43.10% RSI (14)46.24 Volatility1.18% 1.97%
OptionableYes Debt/Eq2.40 EPS Q/Q3.90% Profit Margin10.00% Rel Volume1.03 Prev Close186.68
ShortableYes LT Debt/Eq2.05 EarningsJan 29 AMC Payout134.80% Avg Volume3.23M Price188.34
Recom2.30 SMA20-1.84% SMA50-2.40% SMA200-1.95% Volume3,313,822 Change0.89%
Jan-28-19Downgrade Evercore ISI Outperform → In-line
Oct-01-18Initiated Cantor Fitzgerald Neutral $223
Apr-05-18Reiterated Barclays Equal Weight $190 → $180
Feb-12-18Reiterated Mizuho Buy $192 → $200
Jan-23-18Upgrade Argus Hold → Buy
Nov-01-17Downgrade Argus Buy → Hold
Oct-26-17Reiterated RBC Capital Mkts Sector Perform $192 → $188
Sep-28-17Reiterated Mizuho Buy $183 → $198
Sep-15-17Initiated RBC Capital Mkts Sector Perform $192
Jul-11-17Resumed Jefferies Buy
Jun-23-17Initiated Deutsche Bank Hold $172
Apr-05-17Downgrade Jefferies Buy → Hold
Mar-09-17Initiated UBS Neutral $185
Feb-01-17Upgrade BofA/Merrill Neutral → Buy
Dec-20-16Downgrade Credit Suisse Outperform → Neutral
Dec-13-16Initiated Oppenheimer Outperform
Nov-08-16Initiated Mizuho Buy $164
Aug-26-16Initiated Gabelli & Co Hold
Jun-29-16Initiated Bernstein Mkt Perform
Feb-25-16Initiated Citigroup Neutral $165
Feb-15-19 04:13PM  Amgen Inc. -- Moody's announces completion of a periodic review of ratings of Amgen Inc. Moody's
01:21PM  This Is One Company That Could Break Up Bristol-Celgene Deal Investor's Business Daily
08:01AM  [$$] WSJ Tax Guide 2019: The Drug Industry The Wall Street Journal
Feb-14-19 01:00PM  Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings Zacks
08:41AM  Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down Zacks
Feb-13-19 03:07PM  Key Takeaways from Eli Lilly's (LLY) Q4 Earnings Report Zacks
Feb-12-19 09:12AM  Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer Zacks
09:11AM  AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma Zacks
08:56AM  Sanofi/Regeneron Cut Price of PCSK9 Inhibitor Praluent by 60% Zacks
Feb-11-19 11:45AM  Regenerons 60% Price Cut Shows Heat Is Still on Drug Companies
07:18AM  Sanofi and Regeneron cut list price of cholesterol drug by 60 percent Reuters
07:00AM  Sanofi and Regeneron cut list price of cholesterol drug by 60 pct Reuters
06:11AM  2 Days Left To Cash In On Amgen Inc. (NASDAQ:AMGN) Dividend Simply Wall St.
Feb-08-19 08:03AM  Ligand (LGND) Beats on Q4 Earnings & Sales, Raises '19 View Zacks
Feb-07-19 05:52AM  Amgen Falls 3%
Feb-06-19 09:37AM  Lilly (LLY) Lags Q4 Earnings, Lowers 2019 View, Stock Down Zacks
Feb-05-19 09:02AM  Roche Submits sBLA to FDA for Label Expansion of Kadcyla Zacks
Feb-04-19 09:50AM  Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy Zacks
08:48AM  Pfizer's (PFE) New Lung Cancer Drug Vizimpro Gets CHMP Nod Zacks
Feb-03-19 10:09AM  The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs Benzinga
09:01AM  A War on High Drug Prices Could Boost Biosimilars Motley Fool
Feb-01-19 04:50PM  Roche (RHHBY) 2018 Sales Up on Solid New Drugs Performance Zacks
03:59PM  Exclusive: Top U.S. insurer to cover Amgen, Eli Lilly migraine drugs, exclude Teva Reuters
02:06PM  Why Amgen Should Buy Alexion Pharmaceuticals
08:00AM  Factors of Influence in 2019, Key Indicators and Opportunity within Marathon Oil, Accuray, United Natural Foods, Systemax, Amgen, and NewLink Genetics New Research Emphasizes Economic Growth GlobeNewswire
Jan-31-19 01:51PM  How 5 Goldman Stock Portfolios Are Racing Ahead of The Market Investopedia
12:48PM  Novartis (NVS) Q4 Earnings Miss Estimates, Revenues Up Y/Y Zacks
Jan-30-19 06:04PM  3 Stocks Decline Wednesday
11:31AM  Stocks making the biggest moves midday: Tupperware, AT&T, Boeing, Apple & more CNBC
11:08AM  Biotech Giants Amgen and Biogen Fall on Earnings, Alzheimers News
08:46AM  Amgen (AMGN) Q4 Earnings Beat Estimates, 2019 Guidance Tepid Zacks
08:30AM  Behind the Cutting Edge Technology: The History of Amgen
08:12AM  The Daily Biotech Pulse: Roche Scraps Alzheimer's Disease Trials, Amgen Issues Weak Guidance Benzinga
08:00AM  Today's Research Reports on Trending Tickers: Amgen and OncoCyte ACCESSWIRE
07:52AM  Stocks making the biggest moves premarket: Boeing, Apple, Alibaba, Tesla & more CNBC
07:23AM  Dow Jones Futures: Apple, AMD Drive Premarket Rally Investor's Business Daily
06:26AM  [$$] Stocks to Watch: Apple, AMD, eBay, Amgen, GameStop, Square The Wall Street Journal
06:02AM  Amgen Falls 6%
05:54AM  Amgen Falls 6%
05:40AM  Amgen Falls 6%
05:17AM  Amgen Falls 5%
05:15AM  Amgen Falls 5%
04:30AM  Edited Transcript of AMGN earnings conference call or presentation 29-Jan-19 10:00pm GMT Thomson Reuters StreetEvents
12:14AM  Amgen, Inc (AMGN) Q4 2018 Earnings Conference Call Transcript Motley Fool
Jan-29-19 07:21PM  Amgen Leaves Investors With Mixed Emotions Motley Fool
07:02PM  Amgen 2019 forecast falls short of expectations, shares dip Reuters
05:52PM  Amgen Stock Falls After Hours on Light Forecast Despite Good Quarterly Earnings
05:41PM  Stocks making the biggest moves after hours: Apple, Amgen, AMD and more CNBC
05:03PM  Amgen Tops Fourth-Quarter Forecasts, But Slides On Weak Outlook Investor's Business Daily
05:00PM  Amgen 2019 forecast falls short of expectations, shares dip Reuters
04:53PM  Amgen 2019 forecast falls short of expectations, shares dip Reuters
04:24PM  Amgen: 4Q Earnings Snapshot Associated Press
04:21PM  Amgen stock lower after earnings beat, lower guidance MarketWatch
04:09PM  Amgen falls 3% after 2019 outlook falls short CNBC
04:05PM  Amgen quarterly profit tops Street view, 2019 forecast falls short Reuters
04:01PM  Amgen Reports Fourth Quarter And Full Year 2018 Financial Results PR Newswire
11:06AM  Amgen Earnings, Revenue beat in Q4
09:41AM  Pfizer (PFE) Q4 Earnings Beat, 2019 View Tepid, Stock Dips Zacks
07:25AM  The Daily Biotech Pulse: Big Pharma Earnings, Kiniksa Offering, FDA Decision Day For Aquestive Benzinga
Jan-28-19 04:59PM  Biotech is breaking out. Here's what one analyst says to watch ahead of 3 key earnings reports CNBC
04:21PM  Amgen Slips on Analyst Downgrade
04:15PM  How Novartis Could Throw A Haymaker And Slam Amgen's Sales Investor's Business Daily
10:19AM  Drug/Biotech Stock Earnings on Jan 29: PFE, AMGN, BIIB & AGN Zacks
08:52AM  Amgen downgraded to in-line from outperform by Evercore ISI MarketWatch
04:45AM  Amgen Falls 3%
04:17AM  Amgen (AMGN) to Report Q4 Earnings: What's in the Cards? Zacks
Jan-27-19 04:07PM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings Benzinga
Jan-25-19 03:43PM  Exclusive: CVS to cover migraine drugs from Teva, Lilly; excludes Amgen Reuters
10:34AM  AbbVie (ABBV) Misses on Q4 Earnings & Revenues, Shares Down Zacks
09:43AM  Amgen/Allergan's Rituxan Biosimilar Meets Goal in Phase III Zacks
07:38AM  The Daily Biotech Pulse: Intuitive Surgical Earnings, Corbus To Offer Shares, Eton In-Licenses Neurologic Drug Benzinga
Jan-24-19 04:34PM  Is a Surprise in the Cards for Novartis (NVS) in Q4 Earnings? Zacks
04:30PM  Amgen Announces Webcast of 2018 Fourth Quarter and Full Year Financial Results PR Newswire
04:00PM  Amgen Receives NMPA Approval For Repatha® (evolocumab) In China To Reduce The Risk Of Cardiovascular Events PR Newswire
02:00PM  deCODE Publishes the First Full Resolution Genetic Map of the Human Genome PR Newswire
11:17AM  Pfizer (PFE) to Report Q4 Earnings: What's in the Cards? Zacks
10:59AM  Healthcare ETFs in Focus Ahead of Q4 Earnings Zacks
10:51AM  The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio Zacks
09:27AM  Allergan stock up 0.2% after Phase 1/3 trial of rituximab biosimilar meets primary endpoints MarketWatch
09:00AM  Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab PR Newswire
Jan-23-19 02:33PM  Better Buy: Amgen vs. Johnson & Johnson Motley Fool
10:48AM  5 Best Biotech Bets Likely to Outperform Estimates in Q4 Zacks
09:12AM  Biotech Stock Roundup: Amgen, Vertex Get EC Nod for Label Expansion of Drugs Zacks
Jan-22-19 09:00AM  European Commission Approves BLINCYTO® (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia PR Newswire
Jan-21-19 12:30PM  Top Analyst Reports for Bank of America, Merck & Netflix Zacks
10:10AM  Can Amgen (AMGN) Keep the Earnings Surprise Streak Alive? Zacks
07:50AM  What's in Store for Bristol-Myers (BMY) in Q4 Earnings? Zacks
07:15AM  Biogen (BIIB) Q4 Earnings Coming Up: What's in the Cards? Zacks
Jan-20-19 08:59AM  Which Big Pharma Stocks Lose Most in a War on Drug Price Hikes? Motley Fool
Jan-18-19 05:50PM  Amgen (AMGN) Gains But Lags Market: What You Should Know Zacks
01:18PM  Should You Buy Amgen Inc. (NASDAQ:AMGN) For Its Dividend? Simply Wall St.
Jan-17-19 04:06PM  FDA Committee Recommends Amgen Drug But A Key Question Lingers Investor's Business Daily
10:18AM  Amgen's Postmenopausal Osteoporosis Drug Gets FDA Panel Nod Zacks
08:06AM  The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US Benzinga
Jan-16-19 05:56PM  Amgen's postmenopausal osteoporosis drug wins FDA panel backing Reuters
05:41PM  Amgen And UCB Receive Positive Vote From FDA Advisory Committee In Favor Of Approval For EVENITY (romosozumab) PR Newswire
03:51PM  Amgen's postmenopausal osteoporosis drug wins FDA panel backing Reuters
09:25AM  6 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2019 Zacks
08:24AM  The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen Benzinga
Jan-15-19 04:18PM  Here's How The Government Shutdown Will Affect These Medical Stocks Investor's Business Daily
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound. The company's marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc.; The University of Texas MD Anderson Cancer Center; Provention Bio, Inc.; and Molecular Partners AG. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SUGAR RONALD DDirectorFeb 07Option Exercise54.712,000109,42014,988Feb 11 09:27 PM
SUGAR RONALD DDirectorFeb 07Sale190.002,000380,00012,988Feb 11 09:27 PM
Jacks TylerDirectorDec 06Option Exercise82.6020,0001,652,00028,979Dec 10 08:46 PM
Jacks TylerDirectorDec 06Sale195.4120,0003,908,2328,979Dec 10 08:46 PM
Piacquad DavidSVP, Business DevelopmentNov 30Option Exercise54.696,500355,48545,128Dec 03 08:13 PM
Patton Cynthia MSVP & CCONov 29Option Exercise54.691,77797,18423,090Dec 03 08:11 PM
Patton Cynthia MSVP & CCONov 29Sale202.881,777360,52021,313Dec 03 08:11 PM
HENDERSON REBECCA MDirectorAug 10Option Exercise63.113,000189,33016,197Aug 14 08:29 PM
Harper Sean EEVP, Research & DevelopmentJul 16Sale195.711,525298,45856,082Jul 16 08:20 PM
Harper Sean EEVP, Research & DevelopmentJun 12Sale184.271,525281,01257,510Jun 12 07:07 PM
Harper Sean EEVP, Research & DevelopmentMay 14Sale174.101,525265,50359,035May 15 07:52 PM
Piacquad DavidSVP, Business DevelopmentMay 11Option Exercise54.7115,000820,65051,566May 15 07:55 PM
Harper Sean EEVP, Research & DevelopmentApr 12Sale172.681,525263,33756,788Apr 16 07:03 PM
Harper Sean EEVP, Research & DevelopmentMar 16Sale189.751,525289,36965,682Mar 19 08:52 PM